Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019
dc.contributor.author | Paoletti, Costanza | |
dc.contributor.author | Li, Yufeng | |
dc.contributor.author | Muñiz, Maria C. | |
dc.contributor.author | Kidwell, Kelley M. | |
dc.contributor.author | Aung, Kimberly | |
dc.contributor.author | Thomas, Dafydd G. | |
dc.contributor.author | Brown, Martha E. | |
dc.contributor.author | Abramson, Vandana G. | |
dc.contributor.author | Irvin, William J., Jr. | |
dc.contributor.author | Lin, Nancy U. | |
dc.contributor.author | Liu, Minetta C. | |
dc.contributor.author | Nanda, Rita | |
dc.contributor.author | Nangia, Julie R. | |
dc.contributor.author | Storniolo, Anna M. | |
dc.contributor.author | Traina, Tiffany A. | |
dc.contributor.author | Vaklavas, Christos | |
dc.contributor.author | Van Poznak, Catherine H. | |
dc.contributor.author | Wolff, Antonio C. | |
dc.contributor.author | Forero-Torres, Andres | |
dc.contributor.author | Hayes, Daniel F. | |
dc.contributor.department | Department of Medicine, IU School of Medicine | en_US |
dc.date.accessioned | 2016-04-13T14:29:18Z | |
dc.date.available | 2016-04-13T14:29:18Z | |
dc.date.issued | 2015-06 | |
dc.description.abstract | Purpose: Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhances the prognostic role of CTC. Experimental Design: CTC enumeration and apoptosis were determined using the CXC CellSearch kit at baseline and days 15 and 29 in blood drawn from TN MBC patients who participated in a prospective randomized phase II trial of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with or without tigatuzumab. Association between levels of CTC and patient outcomes was assessed using logistic regression, Kaplan–Meier curves, and Cox proportional hazards modeling. Results: Nineteen of 52 (36.5%), 14 of 52 (26.9%), and 13 of 49 (26.5%) patients who were evaluable had elevated CTC (≥5 CTC/7.5 mL whole blood) at baseline and at days 15 and 29, respectively. Patients with elevated versus not elevated CTC at each time point had worse progression-free survival (PFS; P = 0.005, 0.0003, 0.0002, respectively). The odds of clinical benefit response for those who had elevated versus low CTC at baseline and days 15 and 29 were 0.25 (95% CI: 0.08–0.84; P = 0.024), 0.19 (95% CI: 0.05–0.17; P = 0.014), and 0.06 (95% CI: 0.01–0.33; P = 0.001), respectively. There was no apparent prognostic effect comparing CTC apoptosis versus non-apoptosis. Presence of CTC cluster at day 15 and day 29 was associated with shorter PFS. Conclusions: CTC were detected using CellSearch assay in approximately one-third of TN MBC patients. Elevated CTC at baseline and days 15 and 29 were prognostic, and reductions in CTC levels reflected response. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Paoletti, C., Li, Y., Muñiz, M. C., Kidwell, K. M., Aung, K., Thomas, D. G., … Translational Breast Cancer Research Consortium (TBCRC). (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21(12), 2771–2779. http://doi.org/10.1158/1078-0432.CCR-14-2781 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/9291 | |
dc.language.iso | en | en_US |
dc.publisher | American Association for Cancer Research | en_US |
dc.relation.isversionof | 10.1158/1078-0432.CCR-14-2781 | en_US |
dc.relation.journal | Clinical Cancer Research | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | Author | en_US |
dc.subject | circulating tumor cells | en_US |
dc.subject | breast cancer | en_US |
dc.subject | triple negative | en_US |
dc.title | Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019 | en_US |
dc.type | Article | en_US |